China-based Shanghai Henlius Biotech Inc (2696.HK) and Accord Healthcare Limited, a subsidiary of Intas Pharmaceuticals Ltd, have received approval from the European Commission (EC) for their Zercepac, a biosimilar, trastuzumab, intended for the treatment of certain patients with HER2-positive early breast cancer, HER2-positive metastatic breast cancer and earlier untreated HER2-positive metastatic gastric cancer, it was reported on Wednesday.
The product received approval based on a series of studies including comparative quality studies, preclinical and clinical studies.
Zercepac was developed and produced by Henlius and is the first monoclonal antibody (mAb) and third biosimilar, launched by Accord in Europe, and is the first mAb developed by Henlius to be approved in the European Union.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval